Company intelligence / Profile preview
Oxion Biologics
Stockholm, Swedenoxionbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Lead candidate OX118, a monoclonal antibody targeting OX40L, is entering first-in-human Phase 1 trials in 2025 following preclinical validation showing disease-modifying potential in nonhuman primate models for kidney and heart transplantation and type 2 inflammatory and autoimmune diseases. Additional next-generation antibody fragment-derived assets are in preclinical stage.[1][2][3][5][9]
- Therapeutic areas
- ImmunologyRheumatology
- Modalities
- Monoclonal antibodyAntibody fragment-derived constructBiologic
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Oxion Biologics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Oxion Biologics.